Pfizer targets billions of dollars profit from COVID vaccine, makes $36bn sales in 2021

Pfizer in its third-quarter sales report on November 2, revealed a boost in COVID vaccine sales from $33.5 billion to $36 billion in 2021.

Pfizer CEO, Albert Bourla, disclosed that COVID vaccine brought in $13 billion revenue to the company during the third quarter alone, bringing total revenue to $24.3 billion in 2021.

Pfizer revealed that the company’s profit margin on COVID vaccine, before taxes and after splitting profit with BioNTech, is the “high 20s,” an indication that vaccine profits could hit $10 billion only for this year. The estimated vaccine sales for 2021 is about 80% of what Pfizer believes the rest of its business will earn in 2021.

Pfizer in its earnings report, forecasted revenue of $29 billion from vaccine sales in 2022, based on 1.7 billion doses committed to purchasing contracts.

Pfizer revealed the company will manufacture up to 4 billion doses of vaccine in 2022, leaving 2.3 billion doses it could still sell.

Accordingly, Pfizer has been pushing for a third vaccine dose to expand the market and make more profits at the detriment of the health of the world population.

Pfizer CEO, Albert Bourla, in April, advocated that a third dose of Pfizer’s vaccine was “likely” to be needed within a year of the initial two-dose inoculation, followed by annual vaccinations. By implication, covid will never go away.

According to Bourla: “a likely scenario” is “a third dose somewhere between six and 12 months, and from there it would be an annual re-vaccination.”

Chairman Children’s Health Defense, Robert F. Kennedy, Jr., had declared that “This is strictly about profits and not about public health.”